Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Other Non-Current Assets (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Other Non-Current Assets for 6 consecutive years, with $29.0 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets changed N/A to $29.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $29.0 million for FY2025, N/A changed from the prior year.
  • Other Non-Current Assets for Q4 2025 was $29.0 million at Lexicon Pharmaceuticals, up from $368000.0 in the prior quarter.
  • The five-year high for Other Non-Current Assets was $29.0 million in Q2 2025, with the low at $368000.0 in Q1 2025.
  • Average Other Non-Current Assets over 3 years is $6.9 million, with a median of $828000.0 recorded in 2023.
  • The sharpest move saw Other Non-Current Assets plummeted 87.1% in 2024, then surged 3402.42% in 2025.
  • Over 3 years, Other Non-Current Assets stood at $828000.0 in 2023, then changed by 0.0% to $828000.0 in 2024, then soared by 3402.42% to $29.0 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $29.0 million, $368000.0, and $29.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.